

Carrier Testing Panels for Genetic Diseases

Policy Number: 2025T0586R

Effective Date: July 1, 2025

[Instructions for Use](#)

Table of Contents	Page
Application	1
Coverage Rationale	1
Medical Records Documentation Used for Reviews	2
Definitions	2
Applicable Codes	2
Description of Services	2
Clinical Evidence	3
U.S. Food and Drug Administration	12
References	12
Policy History/Revision Information	13
Instructions for Use	14

Related Commercial/Individual Exchange Policies

- [Cell-Free Fetal DNA Testing](#)
- [Preimplantation Genetic Testing and Related Services](#)
- [Whole Exome and Whole Genome Sequencing \(Non-Oncology Conditions\)](#)

Community Plan Policy

- [Carrier Testing Panels for Genetic Diseases](#)

Medicare Advantage Policy

- [Molecular Pathology/Molecular Diagnostics/Genetic Testing](#)

Application

UnitedHealthcare Commercial

This Medical Policy applies to UnitedHealthcare Commercial benefit plans.

UnitedHealthcare Individual Exchange

This Medical Policy applies to Individual Exchange benefit plans.

Coverage Rationale

Pre-test genetic counseling is strongly recommended in order to inform persons being tested about the advantages and limitations of the test as applied to a unique person.

Reproductive Carrier Screening

Reproductive [Carrier Screening](#) Panels of up to six genes are proven and medically necessary.

Reproductive Carrier Screening Panels of up to 15 genes are proven and medically necessary when an individual and/or their reproductive partner meet at least one of the following criteria:

- Ashkenazi Jewish ancestry (individual/reproductive partner has at least one parent or grandparent of Ashkenazi Jewish descent); or
- A biological [First-](#) or [Second-Degree Relative](#) has been affected by one or more of the conditions evaluated by the Panel

The following are unproven and not medically necessary due to insufficient evidence of efficacy:

- Reproductive Carrier Screening Panels comprised of 16 or more genes
- Carrier Screening for all other indications

Note: It is strongly recommended that reproductive Carrier Screening Panels include screening for cystic fibrosis (*CFTR*) and spinal muscular atrophy (*SMN1*).

Medical Records Documentation Used for Reviews

Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage but does not guarantee coverage of the service requested; refer to the protocol titled [Medical Records Documentation Used for Reviews](#).

Definitions

Carrier Screening: Genetic testing that is performed on an individual who does not have any symptoms of a genetic disorder to determine whether that individual may have a genetic variant associated with a certain disorder that could be passed to biological children [American College of Obstetricians and Gynecologists (ACOG) 2017a, reaffirmed 2023].

First-Degree Relative: First-Degree Relatives include parents, siblings, and children [National Comprehensive Cancer Network (NCCN), 2025].

Gene Panel: Testing panel that looks for genetic changes/variants in more than one gene in the same test (CDC, 2024; MedlinePlus, 2025).

Second-Degree Relative: Second-Degree Relatives include half-siblings, aunts, uncles, grandparents, grandchildren, and nieces/nephews (NCCN, 2025).

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

CPT Code	Description
0400U	Obstetrics (expanded carrier screening), 145 genes by next generation sequencing, fragment analysis and multiplex ligation dependent probe amplification, DNA, reported as carrier positive or negative
81412	Ashkenazi Jewish associated disorders (e.g., Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, and SMPD1
81443	Genetic testing for severe inherited conditions (e.g., cystic fibrosis, Ashkenazi Jewish-associated disorders [e.g., Bloom syndrome, Canavan disease, Fanconi anemia type C, mucopolidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (e.g., ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)
81479	Unlisted molecular pathology procedure

CPT® is a registered trademark of the American Medical Association

Description of Services

Carrier Screening is used to identify individuals or reproductive partners who are at risk of having a child with clinically significant autosomal recessive or X-linked conditions; screening results may impact reproductive decision-making. The use of modern technology such as next-generation sequencing (NGS) enables the use of Panel tests which analyze multiple genes at the same time (Gregg, 2021).

In general, Carrier Screening may be performed for conditions that are found in the general population (pan-ethnic), for diseases that are more common in a particular population (ethnic-based) or based on family history. The American College of Obstetricians and Gynecologists (ACOG) (2022, 2017b, both reaffirmed 2023), recommends screening for

cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies for all women who are considering pregnancy or currently pregnant.

Carrier Screening for Individuals of Ashkenazi Jewish Descent

Certain autosomal recessive conditions are more prevalent in individuals of Ashkenazi Jewish (AJ) descent. Some of these disorders are lethal in childhood or are associated with substantial morbidity. Carrier Screening for individuals of AJ descent is focused on identifying reproductive partners who are at risk of having a child with a disorder that has a higher prevalence in this population. The majority of individuals of Jewish ancestry in North America are of AJ descent and therefore have an increased risk of having a child afflicted with one of these disorders (ACOG, 2017b; reaffirmed 2023).

AJ Carrier Screening Panels may include testing for some or all of the genetic diseases below:

- Tay Sachs disease
- Canavan disease
- Cystic fibrosis (CF)
- Spinal muscular atrophy (SMA)
- Familial dysautonomia
- Bloom syndrome
- Fanconi anemia
- Niemann-Pick disease
- Gaucher disease
- Mucopolysaccharidosis IV
- Maple syrup urine disease
- Joubert syndrome
- Glycogen storage disease 1A
- Familial hyperinsulinism
- Usher 1F and III

Pan-Ethnic Carrier Screening Panels

Historically, Carrier Screening has focused on specific ethnic populations that are known to be at elevated risk of certain clinically significant disorders (e.g., individuals of AJ descent). However, it has become progressively more difficult to classify an individual's true ancestry in today's multi-racial society. As such, the likelihood of being a carrier for a certain disorder may be inconsistent with previous assumptions regarding disease prevalence in the ethnic or racial group with which an individual identifies; this has led to consideration of pan-ethnic screening. Pan-ethnic screening offers Panel testing for certain disorders to all individuals who are pregnant or considering pregnancy, irrespective of ethnicity (ACOG, 2017a, reaffirmed 2023).

Carrier Screening Panels have the capacity to analyze large numbers of genes simultaneously, but there is currently a lack of standardization in conditions screened and Carrier Screening Panel composition. Thus, marketed Panels may include many more genes than would be recommended on an individual basis. Additionally, for every disorder, the gene/mutation/mutation frequency should be known in the population being tested so that negative test results can be translated into an expected residual risk of the disorder (Grody et al., 2013). Unfortunately, many laboratories are unable to calculate the residual risk as they lack knowledge of the carrier frequency within the testing population and the proportion of disease-causing mutations on the assay platform. ACOG suggests Panels targeting conditions with a carrier frequency of at least 1/100, which correlates with a disease incidence of 1/40,000 (ACOG, 2017a, reaffirmed 2023). The American College of Medical Genetics and Genomics (ACMG)'s 2021 practice resource (Gregg et al.) recommends the adoption of a tier-based system built on carrier frequency, with Tier 3 Carrier Screening that includes conditions with carrier frequencies of $\geq 1/200$, plus CF, SMA, and risk-based screening, offered to all individuals who are pregnant or planning a pregnancy.

Genetic counseling is strongly recommended prior to Carrier Screening to inform persons being tested about the advantages and limitations of testing as applied to a unique person. For information regarding noninvasive prenatal testing (NIPT), refer to the Medical Policy titled [Cell-Free Fetal DNA Testing](#).

Clinical Evidence

Carrier Screening for Individuals of Ashkenazi Jewish Descent

Shi et al. (2017) genotyped over 3000 individuals of self-reported Ashkenazi Jewish (AJ) ancestry to analyze the carrier frequency of 29 recessive genetic diseases to determine if additional disorders should be considered as part of routine carrier screening. The team reviewed the literature and the internal database at their lab to identify the genes that should be screened, and utilized pre-existing, de-identified samples from research participants. There were 2252 AJ individuals tested for 29 recessive disorders, and an additional 1390 AJ and 6813 non-AJ individuals were screened for a subset of 18 recessive disorders. The authors identified seven disorders with a carrier frequency of greater than 1 in 100, nine with a carrier frequency between 1 in 100 and 1 in 200, and four between 1 in 200 and 1 in 500. Nine conditions had a carrier frequency of less than 1 in 500 or were not found. Of the 20 diseases with a carrier frequency higher than 1 in 500, two were eye diseases that the authors felt were not appropriate to be included for reproductive related carrier screening. Of the remaining 18 disorders, the team calculated that the cumulative chance for an individual to be a carrier of one of the

18 diseases was 1 in 6. However, the chance that an AJ couple would be carriers of the same disease and be at risk for an affected pregnancy is 1 in 441.

Arjunan et al. (2016) at the Center for Jewish Genetics explored the difference between targeted mutation analysis for Tay Sachs disease, plus enzyme analysis, with next-generation sequencing (NGS). Blood or saliva samples were collected on 506 individuals who underwent NGS for 84 recessive conditions and targeted genotyping. Two hundred and eighty-eight individuals were carriers of at least one condition, represented by 434 pathogenic variants, and eight couples were carriers for the same disorder. When NGS was compared to traditional screening for the diseases routinely screened for in the AJ population, NGS did not find any additional mutations beyond what would have been found by targeted genotyping. However, NGS and the broader panel identified two at-risk carrier couples and 115 (26%) pathogenic variants that would not be found by routine AJ screening.

Pan-Ethnic Carrier Screening

A 2024 Hayes Precision Medicine Insight found minimal support for the use of (ECS in healthy populations to guide reproductive decision-making. Per Hayes, ECS involves testing parents for variants in many genes that can be associated with a variety of recessive disorders. The Hayes conclusion was based on a review of six abstracts of publications addressing the clinical utility of ECS for informing clinical or reproductive decisions. Four professional guidelines addressing ECS were also identified; these guidelines did not show distinct agreement regarding which genes should be included in ECS but generally recommend limiting testing to genes with known clinical impact in terms of reproductive planning. In addition, risks related to ECS, including identification of variants of unknown significance (VUS) and diseases that have a wide range of phenotypic expression, reduced penetrance, or adult onset were identified. Of the four guidelines reviewed, only one was based on a formal evidence review process.

A systematic review and meta-analysis performed by Wang et al. (2023a) sought to evaluate the clinical utility of reproductive carrier screening (RCS). The assessment included eleven studies which incorporated screening for a minimum of three to a maximum of 176 conditions. Across these studies, RCS led to identification of one to 24 high-risk couples per 1000 individuals screened. Based on pooled estimations, the prenatal diagnosis (PND) rate in pregnant high-risk couples was 0.644 (95% CI = 0.364, 0.9230), the termination rate for affected pregnancies was 0.714 (95% CI = 0.524, 0.904), and the rate of in-vitro fertilization (IVF) with preimplantation genetic testing (PGT) was 0.631 (95% CI = 0.538, 0.725). The data analysis revealed a statistically significant reduction in the rate of individuals undergoing PND and termination as the number of conditions in the screening test increased. In addition, carriers that were found to have conditions with greater clinical severity were more likely to terminate pregnancy or chose IVF with PGT. The authors concluded that while the number of conditions screened and the severity of those conditions appear to impact the reproductive decisions of high-risk couples, additional study is required to more clearly define clinical utility and provide evidence to assist with design of appropriate screening panels. The researchers also highlighted the importance of genetic counseling in conjunction with RCS. Publications by Ghiossi et al. (2018), previously discussed in this policy, and Johansen Taber et al. (2019), discussed below, were included in this systematic review.

In a thorough evaluation of currently marketed carrier screening panels, Wang et al. (2023b) evaluated gene content as well as the most common genes/conditions included in 22 existing carrier panels. The number of genes in each panel varied greatly (44 - 2054 per panel). Overall, 2205 cumulative unique genes were included in the 22 panels. Fifteen genes (0.7%) with associated conditions that could be considered “severe” (despite some conditions having only mild or moderate symptoms depending on the specific pathogenic variants in the associated genes) were included in all 22 of the panels. The carrier frequency of the 15 genes, however, varied widely (1 in 49 to < 1 in > 500). Seventeen percent (374) of the 2205 genes were present in 10 or more of the panels and 73.6% were present in five or fewer panels. Approximately one-third of the genes (695, 31.5%) were present in one panel only. These findings demonstrate the significant variation in gene inclusion among manufacturers of carrier gene panels. The authors highlight the lack of consensus on the design of carrier screening panels, while acknowledging the increasing availability of genomic data and sequencing information contributing to the rapidly developing industry of carrier panel screening. They underscore the importance of development of consistent and reliable carrier screening to better service both individuals undergoing testing and the healthcare providers ordering and interpreting the test results.

In an effort to ascertain a carrier screening panel design which is consistent with existing carrier screening recommendations published by the American College of Obstetricians and Gynecologists (ACOG) (2017b) and the American College of Medical Genetics and Genomics (ACMG) (2021), Johansen Taber et al. (2022, included in the 2024 Hayes report) conducted a study of the carrier screening results of 460,608 individuals who had been tested using an NGS panel that screened for up to 176 conditions. Individuals with family or personal history of disease or reported consanguinity were excluded, and 11 races/ethnicities were represented. Forty conditions had carrier frequencies of ≥ 1 in 100 and 75 conditions had carrier frequencies of ≥ 1 in 200. A well-defined phenotype was present for 175 of the conditions and at least one severity criterion and onset early in life were met for 165 conditions. Overall, 37 conditions met

conservative thresholds (including carrier frequency of ≥ 1 in 100) and 74 conditions met more liberal thresholds (including carrier frequency of ≥ 1 in 200). In a panel which tests for 37 conditions, all 7 conditions currently recommended by both ACOG and ACMG for screening in at least one race/ethnicity would be included; this panel would detect 63% of carriers and 84.6% of at-risk couples (ARCs) (as compared to a 176-condition panel). In a more liberal panel, testing for 74 conditions, 81.4% of carriers and 96.6% of ARCs would be detected. The authors concluded that panels including screening for either the 37 conditions based on the conservative threshold or the 74 conditions based on the more liberal threshold would both be consistent with established guidelines. A noted limitation is that conditions beyond what was included in this study may meet ACOG or ACMG guideline criteria. In addition, although the researchers took steps to ensure accuracy of carrier frequency data, there is potential for over- or under-estimation. The development of transparent and consistent panel design which aligns with evidence-based guidelines is recommended.

Ramdaney et al. (2022) conducted a systematic evidence review to evaluate the client and provider experiences for ECS. The authors reviewed literature between January 1, 2003, and May 31, 2021, and found 36 articles that fit the inclusion criteria. Sixteen of the articles evaluated test outcomes, 10 articles evaluated provider outcomes, and 20 articles evaluated client outcomes. For the evaluation of client outcomes, the authors focused on the uptake rates of ECS, the yield of carrier couples, and the influence on reproduction decision-making. It was noted that the uptake rate in clients in the general population was 39% which was consistent with other studies. The uptake of ECS among partners varied between 42% and 77% and the main impacting factors were presence of the partner at the initial appointment, disease severity, and ease of logistical factors. The yield of carrier couple rates ranged from 0.1% to 16.9%; however, the specific populations, panels used, and conditions/genes/mutations assessed varied widely. When evaluating *in silico* studies using modeled data for yield of carrier couples, it was noted that screening for only cystic fibrosis (CF) and spinal muscular atrophy (SMA) would have missed at least 881 of 966 (ARCs). The authors noted that decision-making following actual carrier screening results varied greatly depending on whether the clients were preconception or already pregnant. With preconception, most clients elected to pursue or indicated interest in PGT to minimize the risk of an affected pregnancy. For those clients who received PGT and did not pursue or take direct action given the results, some clients noted benefit from a planning and preparation standpoint. For those clients that were already pregnant, ARCs were less likely to alter their reproductive plans than those clients who received results during the preconception period. The authors evaluated the provider influence on reproduction decision-making and noted that more than half of the provider groups analyzed did not offer ECS to their clients and many of the studies were conducted before newer guidelines regarding ECS were published. It was also noted that the time required for proper education and follow-up were a concern for genetic counselors. Limitations included significant inconsistency in methodologies and population which limited the ability to assess the impact of ECS within the United States. There was a lack of studies documenting outcomes for minimal guideline-based carrier screening compared to ECS. Additionally, most of the studies included were observational and the majority were rated poor/very poor quality or had a high risk of bias.

Leung et al. (2021) developed a method of calculating disease prevalence, ethnic carrier frequency, detection rate (DR), and recurrence risks (RR) metrics across four autosomal recessive conditions (*ABCC8*, *ASPA*, *GAA* and *MMUT*), using CF as proof of concept. A step-by-step approach for calculating DR and RR was based on the sum of disease allele frequencies of pathogenic variants found in literature. Following CF guidelines, carrier frequencies for five ethnicities were gathered from published studies and public databases. If no specific carrier frequency was available, they were derived from the Hardy-Weinberg equation. If neither were available, a default carrier frequency of 1 in 500 was used. The disease allele frequencies of the four genes were compared among three laboratories and possible reasons of discrepancy were explored. The study revealed that multiple laboratories testing the same genes demonstrated a wide range of DR and RR. Possible explanations for this discrepancy include differences in calculation method for DR, differences in definitions for DR or laboratories calculating a DR that is more consistent with the definition of analytical sensitivity (which may increase RR), known technical challenges of NGS that may limit detection of variants, and timing of publications that may also lead to frequency reporting discrepancies. The authors emphasized that accurate DR and RR statistics are critical for reproductive decision-making and stated that there is a need for professional societies to offer official recommendations to avoid laboratories using disparate criteria in setting their preferred lowest DR.

To address concerns regarding the impact of ECS on health care utilization, Kauffman et al. (2021) conducted a randomized controlled trial examining the effects of disclosing negative (normal) ECS on utilization compared with usual care (UC). The authors assessed differences between women randomized to ECS ($n = 127$) and UC (177) by evaluating utilization of mental health services including outpatient, inpatient, and medication use, utilization of outpatient primary care, outpatient specialty care, and inpatient and outpatient mental health services in the year following randomization, and utilization of pregnancy-related services in the five years prior to and at any point following randomization with a documented pregnancy. The authors did not find any evidence of harms on health care utilization in women who had a negative ECS. There were no significant differences in outpatient mental health service use between study arms in the period between randomization and results disclosure or in the 12-month follow-up period after results disclosure. Additionally, there were no significant differences in use of primary care and specialty care services in the year following

results disclosure and no significant differences in utilization of pregnancy-related services following ECS. Of the 304 participants that had data analyzed, there were only 2 cases noted in which ECS led to inappropriate health care utilization: One individual misunderstood the carrier result and sought treatment for hemochromatosis, and one individual attempted to refuse first trimester prenatal screening because she did not understand how it differed from ECS. Limitations for this study include the possibility of refusals of standard-of-care treatment that were not documented, lack of racial/ethnic and socioeconomic diversity, and exclusion of male partners. The authors note that future studies should continue to evaluate the possibility of harms of screening, specifically for non-White and low-income populations.

Kaseniit et al. (2020) quantitatively examined the efficacy and equity with which ethnicity-based carrier screening captures disease risk for recessive conditions. A 96-gene ECS panel was performed on 93,419 individuals; correspondence was assessed among carrier status, self-reported ethnicity, and a dual component genetic ancestry calculated from sequencing data. The authors reported that substantial and disproportionate risk for recessive disorders is not detected when carrier screening is based on ethnicity, which leads to inequitable reproductive care. This conclusion was made after establishing that self-reported ethnicity was an inaccurate predictor of genetic ancestry, with 9% of individuals having > 50% genetic ancestry from a lineage inconsistent with self-reported ethnicity. Self-reported ethnicity resulted in missed carriers in at-risk populations; for 10 ECS conditions, individuals with intermediate genetic ancestry backgrounds who did not self-report the associated ethnicity had significantly elevated carrier risk. For 7/16 conditions included in current screening guidelines, most detected carriers were not from the population that the guideline was aiming to serve. The algorithm from this study can be used across laboratories when considering genes for ECS panel inclusion according to the authors.

Arjunan et al. (2020) utilized a published algorithm that stratifies diseases into four classes of severity (mild, moderate, severe, and profound) for 176 genes screened by ECS; objective severity classifications were then assigned. Previous reports from ACOG/ACMG have not defined how to interpret severity criteria for genes included in ECS. Severity categories based on disease traits were mapped to four severity-related ECS panel criteria from ACOG. Four medical geneticists and eight genetic counselors applied the severity algorithm to subsets of 176 genes. A group consensus was made on how disease traits mapped to ACOG severity criteria. 39% (n = 68) of genes were classified as profound, 40% (n = 71) as severe, 20% (n = 36) as moderate, and 1% (n = 1) as mild. Of 176 total genes, 170 (96.6%) met at least one of the four criteria, 129 (73.3%) met at least two, 73 (41.5%) met at least three, and 17 (9.7%) met all four. The authors noted that the medical geneticists and genetic counselors who reviewed the conditions for this study may not be replicated in practice by clinicians with either similar or different expertise. In addition, the medical geneticist reviewers were not blinded to the genetic counselors' final classifications, so it is possible they were influenced by the genetic counselors' reviews. Lastly, the genes in the study were based on what is available in the current literature, which may skew toward more severe presentation, especially for rare diseases.

ACOG proposed that disorders included in ECS panels should have a carrier frequency of 1/100 or greater, detrimental impact on quality of life and a well-defined phenotype. Balzotti et al. (2020) utilized a ClinGen framework to determine clinical validity of gene-disease relationship for 208 autosomal recessive and X-linked conditions offered in commercially-available ECS panels by Myriad Women's Health (Foresight) and Baylor Genetics (GeneAware). All conditions met the evidence threshold for supporting a gene-disease association. Ninety-eight percent of conditions (203/208) reached the strongest (definitive) level of gene-disease association; of the remaining five, four were classified as having moderate evidence and one was classified as having limited evidence. Twenty-one gene-disease pairs were curated independently by Myriad and Baylor to determine the level of concordance of classification between the two laboratories. The authors surmised that the majority of ECS panel conditions have demonstrable support for gene-disease association, which is a crucial component of ECS clinical validity and ACOG-recommended inclusion criteria for ECS panels. Limitations included potential inconsistencies in how conditions were categorized (potentially skewing results), and the possibility of the emergence of new evidence that may change the classifications used.

Rosenblum et al. (2020) performed a retrospective study to compare the carrier detection rate between a pan-ethnic panel (87 disorders) and an AJ ethnic-specific panel (an 18-disorder subset of the pan-ethnic panel) for 2398 individuals who self-identified as being of AJ descent with no personal or family history of a genetic disorder. The pan-ethnic panel, which assessed 434 targeted, pre-defined variants in 87 genes that cause 87 disorders, was tested in 1150 individuals, and the AJ-specific panel, assessing a subset of 147 variants in 18 genes that cause 18 disorders, was tested in 1248 individuals. The pan-ethnic panel identified 431 individuals (37.5%) as carriers of at least one disorder and 87 of these (76%) were carriers of 2 or more disorders. For the AJ panel, 319 (25.6%) individuals were determined to be carriers of at least one disorder and 60 (4.8%) of these individuals were carriers for multiple disorders. The researchers also re-analyzed the pan-ethnic data for the 18 genes in the AJ-specific panel for those individuals who were found to be a carrier of one of the 87 genes in the pan-ethnic panel. The carrier detection rate would have been 24.3% (280/1,150); the researchers state that 151 individuals would have been missed for carrier detection. The researchers conclude that this data may contribute to further professional discussion on the clinical utility of ECS.

Westemeyer et al. (2020) performed a retrospective analysis of data from a cohort (n = 381,014) receiving ECS of up to 274 genes. The cohort included mostly women (339,739; 89.17%) and various ethnicities: 148,828 (39.06%) Caucasian, 62,626 (16.44%) Hispanic, 52,454 (13.77%) African American, and the remaining 117,106 (30.74%) were either of other races/ethnicities or did not provide information. The majority of individuals (374,911) were tested for CF and 14,229 (3.8%) were found to have a pathogenic or likely pathogenic variant yielding a 1/26 carrier frequency. For CF, 44.0% (6260/14,229) of carriers identified had a variant not on the standard genotyping panel. Similarly, 344,407 individuals were screened for spinal muscular atrophy (SMA) and 14,606 (4.24%, 1/24) were found to be carriers or at-risk silent carriers. Out of the 14,606 carriers for SMA, 8763 (2.54%, 1/39) were at risk for being silent carriers which was not detected by standard screening. In addition, for AJ disorders, 81.6% of carriers identified did not disclose AJ ancestry. For the largest gene panel (274 genes), 60,052 individuals were tested and 38,300 (63.78%) were positive for at least one disorder. The researchers also noted the carrier rates for this large 274-gene panel compared to those in the literature. Of the 274 genes screened, 117 had a carrier rate that differed from what was expected. The researchers concluded that, assuming random pairing across the study population, approximately 1/175 pregnancies would be affected by a disorder in the 274-gene screening panel.

For the majority of ESC panels, there is no consensus on what genes should be included that would be relevant for multiple ethnic groups. Guo and Gregg (2019) conducted an analysis of exome sequencing data (n = 123,136) to determine the carrier rates for six major ancestries (African/African American, Hispanic, AJ, East Asian, non-Finnish European, and South Asian). The study examined 415 genes that are associated with severe recessive conditions and started with determining the variant carrier rates (VCR) to then be able to estimate the gene carrier rates (GCR). Across the ancestries, the highest GCR for a single gene was determined to be for African/African American at 12% for *HBB*. The carrier rates declined for most ancestries; only 30 of the genes in the AJ group had a carrier rate > 1%. Likewise, in the Hispanic population only 6 of the genes had a GCR > 1%. Overall, the researchers found that 32.6% (East Asian) to 62.9% (AJ) of individuals are variant carriers; however, screening all 415 genes would only identify 0.17-2.52% of couples as at risk.

Johansen Taber et al. (2019) reported on survey results from female partners of 391 ARCs who participated in ECS of 176 genetic conditions. The cohort was identified from over 270,000 individuals who underwent screening via the laboratory's ECS panel from September 1, 2015, to December 31, 2017. Females were identified from the database who (1) were found to be carriers of a pathogenic or likely pathogenic variant conferring risk for at least one of 176 autosomal recessive or X-linked conditions currently included in the lab's ECS panel, (2) were aged 18 years or older, (3) had consented to being contacted about participating in research at the lab, and (4) for those carrying pathogenic or likely pathogenic variants associated with autosomal recessive conditions, had reproductive partners meeting the same eligibility criteria and were confirmed by the lab as being carriers of a pathogenic variant in the same gene. Couples carrying only variants known to cause mild presentations of biotinidase deficiency (D444H), *NPHS2*-related nephrotic syndrome (R229Q), and 21-OH deficient congenital adrenal hyperplasia (CAH) (*CYP21A2* gene duplication) were excluded. The 1701 ARCs invited to complete the survey were geographically dispersed and encompassed 15 ethnicities and more than 9 religions. The ARCs reported being at-risk for 53 different conditions, with 10% indicating they were at risk for 2 conditions, and 1.8% reporting being at risk for 3 conditions. The actions taken by the ARCs were broken down into those receiving preconception ECS results and those receiving the results during the prenatal period. ECS was performed on 235 preconception ARCs; 77% of these couples indicated they planned or pursued pregnancy management options to avoid having an affected child. Of the 154 ARCs who received the ECS results while pregnant, 37% reported pursuing prenatal diagnostic testing (PNDx). Of those, 36% had affected pregnancies; 40% of affected pregnancies resulted in termination. Of the 63% of cases that did not report PNDx, 75% resulted in live birth; postnatal testing was planned or had been pursued in 62% of those. In addition, 2.1% terminated the pregnancy without PNDx. The authors also surveyed the ARCs for actions and outcomes in subsequent pregnancies. Of those who pursued PNDx through chorionic villus sampling (CVS) or amniocentesis, 29% had affected fetuses, and 75% of those terminated their pregnancies. Limitations of the study included accuracy of participant recollection of actions, possible response bias, and a larger number of ARCs whose current or future pregnancies were at risk for conditions that occur more often in the population, such as CF and fragile X syndrome. However, the authors tried to decrease these effects by analyzing results in aggregate and by condition severity. Overall, this study represents the largest cohort of at-risk and diverse couples screened to date. The authors assert that the study's results indicate that ECS directs changes in pregnancy management that can lead to fewer births of children with clinically significant genetic diseases and suggests that there may be clinical value in screening for diseases that have not traditionally been assessed for in prenatal/preconception screens.

Peyser et al. (2019) compared the efficiency of ECS to ethnic-based screening to identify carriers. A cohort of 4232 individuals seeking fertility treatment was studied. ECS was performed at one genetic testing laboratory for subjects seen between June 2013 and July 2015. Ethnicity was self-reported. Carrier rates based on ECS were calculated. Carrier rates were also determined for the ACOG-recommended ECS tests (ACOG-based screening) and ethnicity-based screening (ACOG and ACMG ethnicity panel recommendations). The ECS test under study was made up of 400 variants of 102

genes associated with 100 genetic conditions. Fragile X CGG repeat size and *SMN1* exon 7 copy-number status for SMA screening were also included in the ECS panel. Carrier rates were calculated for the overall study population and for each ethnic subpopulation, and then compared to determine differences between carrier identification rates by each panel. The ECS panel did not screen for α -thalassemia and maple syrup urine disease 1A (MSUD1A), two conditions included in the ACOG-based screening panel. Therefore, the carrier rate for the ACOG-based screening was calculated without including these two conditions. A total of 4232 individuals were tested (2880 females [68.1%]; 1352 males [31.9%]) for carrier status using ECS. Applying ethnic-based screening recommendations would have resulted in 359 of 4232 (8.5%) individuals identified as carriers. Applying the ACOG-based screening guidelines, 659 of 4232 (15.6%) would have been identified as carriers. With the ECS panel, 1243 (29.4%) of participants were identified as carriers. A large and highly significant difference was found between carrier rates when each panel was applied to the population and then compared to each other. The authors also looked at the data from subpopulations based on self-reported ethnicity. The number of carriers identified increased with the increasing panel size across the total study cohort and in all but three of 14 self-reported ethnicities. In the Southeast Asian and Native American populations, the only increase was seen from ACOG-based screening to ECS resulting in identification of additional carriers. However, the identification of carriers did not change regardless of the panel for the Pacific Islander cohort. Further, looking at the overall population and five subpopulations, carrier rates were statistically different in all three comparisons: Mixed or Other Caucasian, Southern European, Northern European, Unknown/Not Reported, and AJ. In three subpopulations (Hispanic, South Asian, and Middle Eastern), significant differences were observed in ethnic-based screening versus ECS and ACOG-based ethnic screening versus ECS, but not the ethnic-based screening versus ACOG-based screening. Ethnic-based screening versus ECS only provided statistical differences in the African or African American population. However, in two subethnic populations, East Asian and Southeast Asian, the carrier numbers for each panel were not statistically significant. A total of 1206 couples were screened using the ECS panel; 15 (1.2%) were identified as carrier couples. In revealing the ethnicity of each partner, 8/15 (53%) would have been recognized through ethnic-based screening guidelines. In addition to carrier couples, 73 women were found be carriers of Fragile X, with variation in repeat numbers identified and thus variation in classification of the reproductive risk. In conclusion, the authors present data that ECS is superior to ethnic-based genetic screening at identifying genetic disease carriers and carrier couples. The authors argue that their study provides additional evidence that ECS provides a larger amount of preconception information. The study did have noted limitations; study participants who were seeking ECS due to family history of a specific disorder were included in the analysis, which could have elevated the rate of carrier couples found in the study. In addition, learning carrier status for diseases with late onset or variable phenotypes could lead to increased anxiety and confusion for those undergoing ECS.

Terhaar et al. examined outcomes for three unique multigene RCS panels in a 2018 retrospective analysis. Panel sizes varied; genes associated with a minimum of three diseases (trio) to a maximum of 218 diseases (global) were analyzed. Data was reviewed for 75,036 individuals referred by a healthcare provider in the United States. Trio screening was applied to 51,584 samples and 7.2% of those yielded a positive result. A 23-gene panel (standard) was used for the assessment of 19,550 samples with a 13.2% positive rate. Finally, 3902 samples were assessed with the global panel; 35.8% were positive. Overall, 127 conditions were identified at least once in this group. The authors noted that those that seeking the global panel were more ethnically diverse when compared to the other groups. It was not reported in this study if any at risk couples were identified. The researchers speculate that although receiving more genomic information can be beneficial to individuals and providers who want a lot of information to inform medical management, this may also place a burden on clinical care. Most of the disorders identified were inherited in a recessive manner, requiring the clinicians to provide counseling and screening for a reproductive partner. In addition, large panels may identify conditions with mild phenotypes. Common diseases like CF may be familiar to clinicians, but rare diseases may not be. Educational resources for clinicians and patients are needed in order to ensure informed conversations and decision making.

Wilfond et al. (2018) reported on lessons learned from the NextGen study, a prospective study designed to explore the best approaches to genomics-based RCS. The study enrolled women interested in carrier screening, randomizing them to either receive genomic sequencing (n = 133) or receive usual care (no additional screening) (n = 180). If a woman was positive, her male partner was offered genome sequencing to determine the risk of having an affected pregnancy. In the genome sequencing arm, the team chose to report on 728 conditions categorizing the conditions into five classes that participants could opt to learn about. The classes included diseases resulting in a shortened life span, serious conditions, mild conditions, conditions with unpredictable outcomes, adult-onset conditions, and medically actionable conditions related to the individual's personal health (secondary to carrier screening). Overall, 15 at-risk couples were identified; most were at-risk for adult-onset conditions. Eight were carriers for hereditary hemochromatosis, two were carriers for alpha-1-antitrypsin deficiency, one was a carrier for non-syndromic hearing loss, one was a carrier for Factor V Leiden homozygosity, and the remaining were carriers for X-linked disorders. These included spondyloepiphyseal dysplasia, G6PD deficiency, and hemophilia A. Overall, 78% of participants had at least one finding. This leads to concerns about implementation of this approach into clinical workflows. The median time needed by a genetic counselor to prepare for a follow up visit for positive results was 64 minutes. In this study, 26% of women became pregnant before disclosure, adding additional time sensitivity to developing a genomic sequencing-based screening program. The authors noted that

their study design and size did not allow for a complete analysis of clinical utility, but they highlighted some anecdotal evidence that was collected. It was reported that women receiving genomic sequencing-based screening did not seek out more mental health or other services compared to those receiving usual care. They also did not report more anxiety or depression. One participant declined amniocentesis for chromosome abnormalities because she believed the ECS assessed that; this misconception was later corrected. The participant identified as a carrier of hemophilia A did undergo an amniocentesis; the fetus was male and found to carry the pathogenic variant, which altered the birth plan and allowed the neonatal team to intervene early. Finally, the authors noted that their study was small and on an older, more educated population. In conclusion, the researchers noted that genomics-based carrier screening could have significant impact on clinical workflow and resources, but the optimal gene targets need to be identified. Additionally, this testing may not be accessible to low-income individuals. Additional research is needed to address these issues.

Shraga et al. (2017) reported on reliability of self-reported ethnicity versus genetic ancestry for clinical decision-making in the context of genetic carrier screening. A total of 9138 participants were referred by a variety of healthcare providers such as fertility specialists, obstetricians/gynecologists, and genetic counselors from the United States and Spain. The carrier screening test offered consisted of 311 autosomal recessive and X-linked conditions. Ethnicity information was gathered two times, first at the time the test was ordered, and second when self-recorded on the test requisition form. The couples were asked to choose all applicable ethnicities from the following list of options: African, East Asian, European, French Canadian, Jewish, Latin American, Mediterranean, Middle Eastern, Native American, South Asian, Southeast Asian, and/or Other. For the option "Other," individuals could write in the self-identified ethnicity. All "Other" responses were mapped to appropriate categories when applicable, (e.g., Caucasian/White mapped to European). The second self-report was obtained during the post-test appointment with a genetic counselor. During the family history portion of the consultation, individuals were asked to identify their race/ethnicity or where their family originated from. For situations where subjects did not participate in counseling or were unreachable, a "family history" ethnicity was not generated, and these individuals were not considered in that part of the analysis. However, they were still included in the comparison between "requisition form" ethnicity and genetic ancestry. A set of single nucleotide polymorphisms (SNPs) was selected that could accurately determine continental genetic ancestry in the patient population. SNP frequencies were obtained from the ALFRED database, and through a repetitive process, a set of SNPs that could separate the continental groups was selected. Six of the eight continental groups were determined to be well separated. The Middle Eastern and Central Asian groups are closely related to the European and South Asian groups, respectively, and require an extra set of markers to properly estimate population separations. For this reason, it was decided not to use these two groups as separate ancestral populations, and they were removed from the ultimate estimation. The authors also validated the genetic ancestry model by applying a set of 2504 samples with known origin from the 1000 Genomes project. This test showed the set of 1142 SNPs was able to correctly estimate continental ancestry in the included populations. The results also validated the approach of using pre-commuted population allele frequencies. A comparison of the self-reports in the two situations was then performed. First, the ethnicity reported on the requisition form was compared to that provided during the genetic counseling session. For each ethnic group, counts were generated for: 1) each individual who selected it on the requisition form, 2) each individual who identified it during consults, and 3) each individual who did both. Those who selected "Other" on the requisition form were excluded. Consistent patterns were seen in self-reported identification in both situations. For example, 97.7% of participants who selected East Asian on the requisition form identified as East Asian during the genetic counseling session, while 99.2% of participants who identified as having East Asian ancestry during the consult also selected East Asian on the requisition form. However, for ethnicities such as Mediterranean, Native American, and Southeast Asian, the responses between the two sources of self-report were different. Another observed difference was between self-reported ethnicity on the requisition form and genetic ancestry in South Asians and Southeast Asians. However, these differences were diminished when obtaining ethnicity during the genetic counseling session. The differences indicate that there is confusion about the meaning of different labels, indicating that self-reporting of ethnicity cannot be relied upon. When calculating genetic reproductive risk, inaccurate reporting of ethnicity results in inaccurate calculation of risk. Admixed populations were also looked at, and results indicate that carrier rates and residual risks are dependent on genetic ancestry in these populations. For example, in the carrier rate for cystic CF varies from 1.6% to 3.67% in the Latin American population depending on the percent of European ancestry, and the carrier rate for sickle cell anemia varies from 1.3% to 4.6% depending on the amount of African ancestry. Thus, it cannot be assumed that the genetic risk to admixed populations occurs in a consistent manner. The source of ethnic background can have an impact on estimating carrier and recurrence risk and providing appropriate testing and can impact decision making. The authors suggest that in order to mitigate these risks and ensure serious genetic disorders are not missed, ECS panels should be utilized. Despite the disadvantages of ECS, given that self-reporting of ethnicity is unreliable and can lead the provision of an incomplete picture of risks to couples, ECS provides a comprehensive approach. The authors also concluded that genetic ancestry should be determined by appropriate clinical testing rather than self-reporting in order to provide accurate carrier rates, detection rates and residual risks. The retrospective nature of this study is one of its limitations. Another is that self-reported ethnicity could have been incorrectly entered in the database or modified. A third limitation is that the ancestry model used is based on allele frequency estimates from a small sample size and assumes that assembling people by continent provides meaningful estimates of origin. Additional studies with larger cohorts are

needed to improve the ancestry model and to measure the relationship between carrier rates and genetic ancestry for more diseases. Additional work is also needed to understand the factors leading to self-identified ethnicity. In conclusion, self-reported ethnicity is shown to be unreliable, leading to the possibility of inaccurate calculation of carrier rates and residual risk. To decrease the risk of ordering the incorrect testing panel, the authors recommend the use of pan-ethnic ECS panels. In addition, in order to accurately estimate carrier rates and residual risks, they recommend the use of a genetic ancestry model in clinical genetic testing.

Haque et al. (2016) created a model of fetal risk based on a commercial laboratories experience with ECS. From January 2012 to July 2015, the laboratory screened 346,790 individuals that were referred for testing by their healthcare provider. The ECS panel test offered analyzed 110 genes including 94 conditions categorized as severe or profound. Two platforms were utilized. The first was targeted genotyping for 417 known pathogenic variants, and the second was NGS for all genes. Healthcare providers could select the testing platform and genes desired for their patient, so not all individuals were screened for all conditions. Targeted genotyping was performed on 308,668 individuals, and 47,590 carriers were identified, of which 279 individuals were homozygous or compound heterozygous. NGS was completed on 38,122 individuals; of these, 11,088 individuals were carriers and 124 were identified as homozygous or compound heterozygous. Results were reviewed in the context of the participant gender and self-reported race/ethnicity. The largest racial mix in the study was “mixed or other Caucasian.” The smallest group included in the analysis was Southeast Asian; Finnish was the smallest overall and was excluded from the final analysis due to small numbers. The authors used the results of both platforms to estimate carrier frequency by ethnic group, then modeled the carrier frequency, carrier couple frequency for couples of the same ethnicity, and resulting fetal risk. Based on the model, the authors then compared the detection rate of potential at-risk couples for diseases included in current professional society carrier screening guidelines against the detection rate of all profound and severe diseases in the ECS panel. When hemoglobinopathy genes are excluded from analysis, African Americans were noted to have 18% risk of profound or severe recessive diseases covered by guidelines, and 82% risk outside of guidelines, with a calculated cumulative risk of one in 1,741 to have a fetus affected by any profound/severe condition in the study. The AJ group had 45% risk within guidelines and 55% risk outside of guidelines with a modeled fetal risk of one in 255. Mixed or other Caucasian had 32% risk within guidelines, and 68% risk outside of guidelines with a modeled fetal risk of one in 649. The authors conclude that current guidelines do not perform equally well between self-reported ethnic groups and currently target diseases prevalent in European populations. ECS may identify couples at risk for other conditions that are important in a diverse population. Limitations identified for the study include the use of an artificial construct to calculate disease frequencies and fetal results from random mating within an ethnic group. Disease frequencies in the general population might vary when compared to the population referred for genetic testing by a healthcare provider. The model does not fully address the racial/ethnic admixture possible in the study population or in real world reproductive pairing. Prospective studies comparing current standard of care with ECS are needed before ECS is fully adopted.

Clinical Practice Guidelines

American College of Obstetricians and Gynecologists (ACOG)

In a 2022 (reaffirmed 2024) Practice Advisory, ACOG updated their recommendations on hemoglobinopathies in pregnancy, noting that previous recommendations for testing were based on race/ethnicity. This strategy is no longer recommended because self-reported race/ethnicity is not always accurate in terms of genetic ancestry. Since about 1 in 66 individuals in the United States have a trait related to hemoglobinopathy, ACOG recommends offering hemoglobinopathy testing (which may be performed using hemoglobin electrophoresis or molecular genetic testing) to all individuals planning a pregnancy or at the first prenatal visit if no prior testing for hemoglobinopathies has been performed. Following this model, individuals who are at-risk can receive important counseling regarding their genetic risk, explore potential options, and make informed decisions.

In Committee Opinion 690 (2017a, reaffirmed 2023), ACOG states that all individuals who are pregnant or considering pregnancy should be offered carrier screening for cystic fibrosis (CF), spinal muscular atrophy (SMA) and complete blood count and screening for thalassemias and hemoglobinopathies. If ECS is to be considered, several of the following consensus-driven criteria should be met:

- The disorder should have a carrier frequency greater than 1 in 100
- The condition should have a well-defined phenotype, a detrimental effect on quality of life, cause physical or cognitive impairment, and have onset early in life
- Diagnosis can be made prenatally to provide opportunities for antenatal intervention to improve perinatal outcomes such as changes in delivery management, and to educate parents about special needs after birth
- Carrier screening panels should not include adult-onset conditions

ACOG advises that not all individuals who are at risk of the conditions screened will be identified through carrier screening and stresses the importance of genetic counseling for all individuals undergoing carrier screening.

In ACOG Committee Opinion No. 691 (2017b, reaffirmed in 2023), carrier screening for the four diseases below was recommended for individuals of Ashkenazi Jewish (AJ) descent:

- Canavan disease (carrier frequency 1/40)
- Cystic fibrosis (carrier frequency 1/29)
- Familial Dysautonomia (carrier frequency 1/32)
- Tay-Sachs disease (carrier frequency 1/30)

The Committee Opinion points out that more comprehensive screening panels for individuals of AJ descent have been promoted by some experts, to include less-common diseases with carrier rates from 1/15 to 1/168. These include:

- Bloom syndrome
- Familial hyperinsulinism
- Fanconi anemia
- Gaucher disease
- Glycogen storage disease
- Joubert syndrome
- Maple syrup urine disease
- Mucopolysaccharidosis type IV
- Niemann-Pick disease
- Usher syndrome

When only one partner is of AJ descent, that individual should be offered screening first, and if found to be a carrier, the other partner should then be offered screening. Of note, carrier frequency and detection rate in non-Jewish individuals are unknown for the majority of disorders discussed above, so accuracy in predicting risk is likely reduced.

American College of Medical Genetics and Genomics (ACMG)

An ACMG Practice Resource (Gregg et al., 2021) identifies and recommends adoption of a tiered approach to carrier screening.

- Tier 1 – Cystic Fibrosis (CF) + Spinal Muscular Atrophy (SMA) + Risk Based Screening
- Tier 2 – $\geq 1/100$ carrier frequency (includes Tier 1)
- Tier 3 – $\geq 1/200$ carrier frequency (includes Tier 2 and X-linked conditions)
- Tier 4 – $< 1/200$ carrier frequency (includes Tier 3)

In addition, the ACMG resource includes the following recommendations:

- The term “carrier screening” should replace the term “expanded carrier screening”
- Promotion of paradigms for carrier screening that are ethnic and population neutral
- Tier 3 carrier screening for autosomal recessive and X-linked conditions should be offered to all pregnant patients and those planning a pregnancy
- Tier 3 carrier screening for autosomal recessive conditions may be offered to reproductive partners of pregnant individuals or those planning pregnancy when screening is performed simultaneously with their partner
- Tier 4 screening should only be considered if a pregnancy stems from a known or possible consanguineous relationship (second cousins or closer) or when a family or personal medical history warrants such testing

National Society of Genetic Counselors

The National Society of Genetic Counselors (Sagaser et al.) published an evidence-based practice guideline in 2023, recommending that ECS be offered to all individuals considering reproduction, pregnant individuals, and their partners and those who might otherwise contribute biologically to the pregnancy. They assert that the final decision regarding carrier screening should take place after shared decision-making, considering the specific features of individuals and their personal values and preferences. Use of ECS provides an alternative to ethnicity-based screening and would potentially identify more carriers of autosomal recessive and X-linked conditions without dependence on race. The authors note that this recommendation is conditional and is “based on the balance of benefits and harms of ECS, and low and moderate certainty in the evidence. There are no specific clinical criteria or set of conditions associated with the conditional recommendation for ECS.” Efforts to focus on addressing barriers to ECS, including insurance coverage, access to genetics professionals and educational needs of impacted individuals, are recommended.

Royal College of Obstetricians and Gynaecologists (RCOG)

In a 2024 scientific impact paper (number 74), Elson et al. summarize the use of expanded carrier screening (ECS) in reproductive medicine, including discussion of clinical, technical, and ethical considerations as well as value and risk. The authors indicate that while targeted carrier screening before conception is appropriate for individuals who are at high risk

of carrying a gene that is known to cause severe disease, there is insufficient evidence to recommend testing all prospective parents routinely. They further point out that there is lack of standardization among ECS panels currently on the market; providers are encouraged to gain a thorough understanding of the specific panel used before interpretation of results is performed. Interpretation should be performed only by clinicians with appropriate knowledge of clinical genetics. Lastly, the authors point out that further work to determine the appropriate genes for inclusion in ECS panels, considering population/ethnicity variation and the potential benefits to individuals and their offspring while minimizing unnecessary screening, is needed.

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Laboratories that perform genetic tests are regulated under the Clinical Laboratory Improvement Amendments (CLIA) Act of 1988. More information is available at:

<https://www.fda.gov/medicaldevices/deviceregulationandguidance/ivdregulatoryassistance/ucm124105.htm>.

(Accessed March 6, 2025)

Refer to the following website for a list of nucleic acid-based tests/platforms that have been cleared or approved by the FDA's Center for Devices and Radiological Health: <https://www.fda.gov/medical-devices/in-vitro-diagnostics/nucleic-acid-based-tests>. (Accessed April 3, 2025)

References

- American College of Obstetricians and Gynecologists. Committee Opinion No. 690: Carrier screening in the age of genomic medicine. *Obstet Gynecol*. 2017a Mar;129(3):595-596. Reaffirmed 2023.
- American College of Obstetrics and Gynecologists. Committee Opinion No. 691: Carrier screening for genetic conditions. *Obstetrics and Gynecology*. Mar 2017b;129(3):e41-e55. Reaffirmed 2023.
- American College of Obstetricians and Gynecologists. Practice Advisory: Hemoglobinopathies in Pregnancy. August 2022, reaffirmed September 2024. Available at: <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/08/hemoglobinopathies-in-pregnancy>. Accessed March 6, 2025.
- Arjunan A, Bellerose H, Torres R, et al. Evaluation and classification of severity for 176 genes on an expanded carrier screening panel. *Prenatal Diagnosis*. 2020 Sep;40(10):1246-1257.
- Arjunan A, Litwack K, Collins N, Charrow J. Carrier screening in the era of expanding genetic technology. *Genet Med*. 2016 Dec;18(12):1214-1217.
- Balzotti M, Meng L, Muzzey D, et al. Clinical validity of expanded carrier screening: Evaluating the gene-disease relationship in more than 200 conditions. *Human Mutation*. 2020 May; 41(8):1365-1371.
- Centers for Disease Control and Prevention (CDC) Genomics and Your Health. Genetic Testing. May 15, 2024. Available at: <https://www.cdc.gov/genomics-and-health/counseling-testing/genetic-testing.html>. Accessed March 7, 2025.
- Elson J, Drakeley A, Achilli C, et al; Royal College of Obstetricians and Gynaecologists. The use of expanded Carrier Screening in Reproductive Medicine: Scientific Impact Paper No. 74. *BJOG*. 2024 Sep;131(10):e81-e85.
- Ghiossi CE, Goldberg JD, Haque IS, et al. Clinical utility of expanded carrier screening: Reproductive behaviors of at-risk couples. *J Genet Couns*. 2018 Jun;27(3):616-625.
- Gregg AR, Aarabi M, Klugman S, et al.; ACMG Professional Practice and Guidelines Committee. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2021 Oct;23(10):1793-1806.
- Grody WW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening. *Genet Med*. 2013 Jun;15(6):482-3.
- Guo MH, Gregg AR. Estimating yields of prenatal carrier screening and implications for design of expanded carrier screening panels. *Genet Med*. 2019;21(9):1940-1947.
- Haque IS, Lazarin GA, Kang HP, et al. Modeled fetal risk of genetic diseases identified by expanded carrier screening. *JAMA*. 2016 Aug 16;316(7):734-42.
- Hayes, Inc. Precision Medicine Insight. Expanded carrier screening. Hayes, Inc.; April 18, 2024.

Johansen Taber KA, Beauchamp KA, Lazarin GA, et al. Clinical utility of expanded carrier screening: results-guided actionability and outcomes. *Genet Med*. 2019 May;21(5):1041-1048.

Johansen Taber K, Ben-Shachar R, Torres R, et al. A guidelines-consistent carrier screening panel that supports equity across diverse populations. *Genet Med*. 2022 Jan;24(1):201-213.

Kasaniit K, Haque I, Goldberg J, et al. Genetic Ancestry analysis on > 93,000 individuals undergoing expanded carrier screening reveals limitations of ethnicity-based medical guidelines. *Genet Med*. 2020 Oct;22(10): 1694-1702.

Kauffman TL, Dickerson JF, Lynch FL, et al. Impact of expanded carrier screening on health care utilization. *Am J Manag Care*. 2021 Aug;27(8):316-321.

Leung M, McAdoo S, Watson D, et al. A transparent approach to calculate detection rate and residual risk for carrier screening. *J Molec Diagn*. 2021 Jan;23(1):91-100.

MedlinePlus [Internet]. Bethesda (MD): National Library of Medicine (US); (updated June 24, 2020). Help me understand genetics (updated July 28, 2021). Available at: <https://medlineplus.gov/genetics/understanding/testing/types/>. Accessed March 7, 2025.

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: breast, ovarian, pancreatic and prostate. Version 3.2025. March 6, 2025.

Peyser A, Singer T, Mullin C, et al. Comparing ethnicity-based and expanded carrier screening methods at a single fertility center reveals significant differences in carrier rates and carrier couple rates. *Genet Med*. 2019 Jun;21(6):1400-1406.

Ramdaney A, Lichten L, Propst L, et al. Expanded carrier screening in the United States: A systematic evidence review exploring client and provider experiences. *J Genet Couns*. 2022 Aug;31(4):937-948.

Rosenblum LS, Zhu H, et al. Comparison of pan-ethnic and ethnic-based carrier screening panels for individuals of Ashkenazi Jewish descent. *J Genet Couns*. 2020;29(1):56-66.

Sagaser KG, Malinowski J, Westerfield L, et al. Expanded carrier screening for reproductive risk assessment: An evidence-based practice guideline from the National Society of Genetic Counselors. *J Genet Couns*. 2023 Jun;32(3):540-557.

Shi L, Webb BD, Birch AH, et al. Comprehensive population screening in the Ashkenazi Jewish population for recurrent disease-causing variants. *Clinical genetics*. 2017;91(4):599-604.

Shraga R, Yarnall S, Elango S, et al. Evaluating genetic ancestry and self-reported ethnicity in the context of carrier screening. *BMC Genet*. 2017 Nov 28;18(1):99.

Terhaar C, Teed N, Allen R, et al. Clinical experience with multigene carrier panels in the reproductive setting. *Prenat Diagn*. 2018 Apr 23;38(8):572-7.

Wang T, Kiss D, McFadden K, et al. Clinical utility of reproductive carrier screening for preconception and pregnant couples for multiple genetic conditions: a systematic review and meta-analysis. *Expert Rev Mol Diagn*. 2023a May;23(5):419-429.

Wang T, Scuffham P, Byrnes J, et al. An overview of reproductive carrier screening panels for autosomal recessive and/or X-linked conditions: How much do we know? *Prenat Diagn*. 2023b Oct;43(11):1416-1424.

Westemeyer M, Saucier J, Wallace J, et al. Clinical experience with carrier screening in a general population: support for a comprehensive pan-ethnic approach *Genet Med*. 2020 Aug;22(8):1320-1328.

Wilfond BS, Kauffman TL, Jarvik GP, et al. Lessons learned from a study of genomics-based carrier screening for reproductive decision making. *Health Aff (Millwood)*. 2018 May;37(5):809-816.

Policy History/Revision Information

Date	Summary of Changes
07/01/2025	<p>Definitions</p> <ul style="list-style-type: none"> Updated definition of “Gene Panel” <p>Supporting Information</p> <ul style="list-style-type: none"> Updated <i>Clinical Evidence</i>, <i>FDA</i>, and <i>References</i> sections to reflect the most current information Archived previous policy version 2025T0586Q

Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence ([Medicare IOM Pub. No. 100-16, Ch. 4, §90.5](#)).

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.